Novoprotein(SH:688137)2026-02-27 10:30Financial Performance - The company achieved total operating revenue of RMB 151.51 million, representing an 18.78% year-on-year increase[5] - The net profit attributable to the parent company was a loss of RMB 76.18 million, a 40.00% increase in loss compared to the previous year[5] - The total assets at the end of the reporting period were RMB 2,153.47 million, a decrease of 2.91% from the beginning of the period[5] - The equity attributable to the parent company was RMB 2,036.32 million, down 3.11% from the beginning of the period[5] - The basic earnings per share were -RMB 1.09, compared to -RMB 0.78 in the previous year[5] Research and Development - The company increased its R&D expenses to strengthen its technological advantages in RNA drugs, antibody drugs, and synthetic biology[7] Marketing and Sales - Sales expenses increased as the company expanded its marketing team and focused on overseas market development[7] Business Growth and Challenges - The company faced challenges in the industry but continued to grow its main business revenue through product line expansion and new business development[6] Other Income and Expenses - Government subsidies decreased compared to the previous year, impacting other income[8] - Deferred tax expenses increased due to the cautious approach regarding future taxable income, affecting current profits[9]